Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1695-1700

  Kalousová, Marta ^a   Krechler, Tomáš ^a   Jáchymová, Marie ^a   Kuběna, Aleš A ^a   Žák, Aleš ^a   Zima, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Ferritin; Mortality; Pancreas cancer; Predictor; Prognosis; Tumour marker

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHOLINESTERASE; FERRITIN; HEMOGLOBIN; IRON; LIPID; PREALBUMIN;

AGED; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; IRON BLOOD LEVEL; KIDNEY FUNCTION TEST; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS FUNCTION TEST; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; UNIVARIATE ANALYSIS;

EID: 84868136449     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0426-z     Document Type: Article

References (22)

1. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773-83.
2. Key C. Cancer of the pancreas. In: Ries LAG, Young JL, Keel GE, Eisner MN, Lin ZD, Horner M-J, editors. SEER survival monograph: cancer survival among adults: US SEER program, 1988-2001, patient and tumor characteristic. Bethesda: National Center Institute; 2007.
3. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758-68.
4. Bassi C, Stocken DD, Olah A, Friess H, Buckels J, Hickey H, et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig Surg. 2005;22(5):353-63.
5. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141(5):610-8.
6. Sierzega M, Popiela T, Kulig J, Nowak K. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas. 2006;33(3):240-5.
7. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2004;70(3):235-40.
8. Weber A, Kehl V, Mittermeyer T, Herberich E, Röthling N, Schmid RM, Prinz C. Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas. 2010;39(8):1247-53.
9. Shimoda M, Katoh M, Kita J, Sawada T, Kubota K. The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy. 2010;56(6):501-6.
10. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21(3):441-7.
11. Katz MH, Savides TJ, Moossa AR, Bouvet M. An evidence-based approach to the diagnosis and staging of pancreatic cancer. Pancreatology. 2005;5(6):576-90.
12. Balch CM, Fleming ID, Fritz A, Greene FL, Haller DG, Morrow M, et al. AJCC Cancer staging Handbook, sixth ed. Springer Verlag, New York; 2002
13. Giler S, Moroz C. The significance of ferritin in malignant diseases. Biomedicine. 1978;28(4):203-6.
14. Nitti D, Fabris C, Del Favero G, Farini R, Grassi F, Farini A, et al. Serum ferritin in pancreatic disease. An accurate test of malignancy? Digestion. 1982;25(4):258-62.
15. Fabris C, Farini R, Del Favero G, Grassi F, Nitti D, Piccoli A, et al. Combined evaluation of serum ribonuclease and ferritin: any advantages in pancreatic cancer diagnosis? Oncology. 1984;41(6):393-5.
16. Fabris C, Farini R, Piccoli A, Del Favero G, Panucci A, Plebani M, et al. CEA and ferritin in chronic pancreatic disease: a comparative evaluation. Hepatogastroenterology. 1985;32(3):146-8.
17. Plebani M, Fabris C, Basso D, Del Favero G, Angonese C, Leandro G, et al. Limits of CEA and ferritin in the diagnosis of pancreatic cancer. Int J Pancreatol. 1988;3 Suppl 1:S113-7.
18. Basso D, Fabris C, Del Favero G, Meggiato T, Panozzo MP, Vianello D, et al. Hepatic changes and serum ferritin in pancreatic cancer and other gastrointestinal diseases: the role of cholestasis. Ann Clin Biochem. 1981;28(Pt 1):34-8.
19. Morita R, Yoshii M, Nakajima K, Kohsaka T, Miki M, Torizuka K. Clinical evaluation of serum ferritin to iron ratio in malignant diseases. Eur J Nucl Med. 1981;6(7):331-6.
20. Kukulj S, Jaganjac M, Boranic M, Krizanac S, Santic Z, Poljak-Blazi M. Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol. 2010;27(2):268-77.
21. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, et al. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res. 2005;11(9):3175-83.
22. Alkhateeb AA, Connor JR. Nuclear ferritin: a new role for ferritin in cell biology. Biochem Biophys Acta. 2010;1800(8):793-7.